Immunitybio

Immunitybio Financial Debt Ratio

The Financial Debt Ratio of Immunitybio (IBRX) as of Nov 20, 2026 is 174.96 %. In the previous year, Financial Debt Ratio was 131.66 % — a change of 32.89% (higher).

Financial Debt Ratio

174.96 %

YoY

32.89%

Last updated:

Financial Debt Ratio of Immunitybio is 2025 174.96 % . Financial Debt Ratio of Immunitybio was 2024 131.66 % . It decreases by 32.89% higher compared to the previous year.

The Immunitybio Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
3.80 USD
Jan 1, 2019
10.37 USD
Jan 1, 2020
124.47 USD
Jan 1, 2021
137.69 USD
Jan 1, 2022
199.74 USD
Jan 1, 2023
144.06 USD
Jan 1, 2024
131.66 USD
Jan 1, 2025
174.96 USD
The Immunitybio Financial Debt Ratio history
YEARFinancial Debt RatioYoY
174.96 %+32.89%
131.66 %-8.61%
144.06 %-27.88%
199.74 %+45.06%
137.69 %+10.63%
124.47 %+1,099.77%
10.37 %+173.17%
3.80 %+30.86%
2.90 %+12.23%
2.59 %+284.37%
0.67 %+54.42%
0.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunitybio stock

Financial Debt Ratio of Immunitybio is 174.96 % in 2025.

Financial Debt Ratio of Immunitybio changed from 131.66 % to 174.96 %, representing a 32.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Immunitybio since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Immunitybio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Immunitybio

All Key Metrics — Immunitybio